Real-world management of patients with complete response under immune-checkpoint inhibition for advanced melanoma.

IF 5.5 4区医学 Q1 DERMATOLOGY

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-01-02 DOI:10.1111/ddg.15604

Markus Reitmajer, Elisabeth Livingstone, Kai-Martin Thoms, Markus V Heppt, Frank Meiss, Anja Gesierich, Konstantin Drexler, Lucie Heinzerling, Friedegund Meier, Christian Menzer, Max Schlaak, Lisa Zimmer, Andrea Forschner

{"title":"Real-world management of patients with complete response under immune-checkpoint inhibition for advanced melanoma.","authors":"Markus Reitmajer, Elisabeth Livingstone, Kai-Martin Thoms, Markus V Heppt, Frank Meiss, Anja Gesierich, Konstantin Drexler, Lucie Heinzerling, Friedegund Meier, Christian Menzer, Max Schlaak, Lisa Zimmer, Andrea Forschner","doi":"10.1111/ddg.15604","DOIUrl":null,"url":null,"abstract":"Background: Up to now, the optimal duration of immune checkpoint inhibitors (ICI) has not been evaluated in prospective studies. However, current clinical practice requires decisions to be made regarding the duration of ICI in complete responders.Material and methods: A survey was sent to 80 DeCOG skin cancer centers to assess how decisions are made on treatment duration of ICI in melanoma after having reached complete response, and staging intervals after ICI discontinuation. All responses received by March 10, 2024 (51 centers) were included.Results: The duration of ICI after having achieved complete remission varies between centers from three to 36 months. In total, 66% of the DeCOG centers continue treatment for up to 6 months, after having achieved complete remission (CR) with ICI. In the first year after discontinuation of ICI, most centers perform staging intervals (CT/MRI) every 3 months. More than 60% of centers continue staging at least once per year even in the 4th and 5th year after discontinuation.Conclusions: There are significant differences between the centers regarding staging intervals and duration of ICI upon CR. Prospective studies are necessary to determine the optimal time point of ICI discontinuation and follow-up.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal Der Deutschen Dermatologischen Gesellschaft","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ddg.15604","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Up to now, the optimal duration of immune checkpoint inhibitors (ICI) has not been evaluated in prospective studies. However, current clinical practice requires decisions to be made regarding the duration of ICI in complete responders.

Material and methods: A survey was sent to 80 DeCOG skin cancer centers to assess how decisions are made on treatment duration of ICI in melanoma after having reached complete response, and staging intervals after ICI discontinuation. All responses received by March 10, 2024 (51 centers) were included.

Results: The duration of ICI after having achieved complete remission varies between centers from three to 36 months. In total, 66% of the DeCOG centers continue treatment for up to 6 months, after having achieved complete remission (CR) with ICI. In the first year after discontinuation of ICI, most centers perform staging intervals (CT/MRI) every 3 months. More than 60% of centers continue staging at least once per year even in the 4th and 5th year after discontinuation.

Conclusions: There are significant differences between the centers regarding staging intervals and duration of ICI upon CR. Prospective studies are necessary to determine the optimal time point of ICI discontinuation and follow-up.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal Der Deutschen Dermatologischen Gesellschaft 医学-皮肤病学

CiteScore

3.50

自引率

25.00%

发文量

406

审稿时长

1 months

期刊介绍： The JDDG publishes scientific papers from a wide range of disciplines, such as dermatovenereology, allergology, phlebology, dermatosurgery, dermatooncology, and dermatohistopathology. Also in JDDG: information on medical training, continuing education, a calendar of events, book reviews and society announcements. Papers can be submitted in German or English language. In the print version, all articles are published in German. In the online version, all key articles are published in English.